BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. Circ Res. 2017;120:332-340. [PMID: 27856497 DOI: 10.1161/circresaha.116.309717] [Cited by in Crossref: 86] [Cited by in F6Publishing: 50] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 March KL, Pepine CJ. Cardiac Cell Therapy Evolving From Complex to Straightforward: Enabling Adoption and Affordability. Circ Res 2017;121:1116-8. [PMID: 29074527 DOI: 10.1161/CIRCRESAHA.117.311947] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Vicinanza C, Lombardi E, Ros FD, Marangon M, Durante C, Mazzucato M, Agostini F. Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications. WJSC 2022;14:54-75. [DOI: 10.4252/wjsc.v14.i1.54] [Reference Citation Analysis]
3 Papadimitriou L, Hernandez GA, Lennep B, Long RC, Butler J, Kalogeropoulos AP. Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00905-6] [Reference Citation Analysis]
4 Barthélémy I, Thibaud JL, de Fornel P, Cassano M, Punzón I, Mauduit D, Vilquin JT, Devauchelle P, Sampaolesi M, Blot S. In vivo stem cell tracking using scintigraphy in a canine model of DMD. Sci Rep 2020;10:10681. [PMID: 32606364 DOI: 10.1038/s41598-020-66388-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Razeghian-Jahromi I, Matta AG, Canitrot R, Zibaeenezhad MJ, Razmkhah M, Safari A, Nader V, Roncalli J. Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy. Stem Cell Res Ther 2021;12:361. [PMID: 34162424 DOI: 10.1186/s13287-021-02443-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sato Y, Kuragaichi T, Saga S, Nakayama H, Obata T, Watanabe M, Fujikura K, Watanabe M, Hata KI, Ohgushi H. Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction. Circ Rep 2021;3:550-4. [PMID: 34568634 DOI: 10.1253/circrep.CR-21-0091] [Reference Citation Analysis]
7 Poglajen G, Zemljič G, Frljak S, Cerar A, Andročec V, Sever M, Černelč P. Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure. Stem Cells Int 2018;2018:6487812. [PMID: 29535775 DOI: 10.1155/2018/6487812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Turner D, Rieger AC, Balkan W, Hare JM. Clinical-based Cell Therapies for Heart Disease-Current and Future State. Rambam Maimonides Med J. 2020;11. [PMID: 32374254 DOI: 10.5041/rmmj.10401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sava RI, Pepine CJ, March KL. Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. J Clin Med 2020;9:E241. [PMID: 31963368 DOI: 10.3390/jcm9010241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Meenakshi Sundaram R, Kadapakkam Nandabalan S, Rupert S, Srinivasan P, Sankar P, Patra B, Verma RS, Vennila R, Sathyanesan J, Rajagopal S. Differential immunomodulation of human Mesenchymal Stromal Cells from various sources in an inflammation mimetic milieu. Cytotherapy 2021:S1465-3249(21)00787-8. [PMID: 34740526 DOI: 10.1016/j.jcyt.2021.09.005] [Reference Citation Analysis]
11 Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, Albelda MT, Sikora S, Kharazi A, Vertelov G, Waksman R, Epstein SE. Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. Circ Res. 2017;120:1598-1613. [PMID: 28232595 DOI: 10.1161/circresaha.117.310599] [Cited by in Crossref: 87] [Cited by in F6Publishing: 58] [Article Influence: 17.4] [Reference Citation Analysis]
12 Fan M, Huang Y, Chen Z, Xia Y, Chen A, Lu D, Wu Y, Zhang N, Qian J. Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis. Stem Cell Res Ther 2019;10:150. [PMID: 31151406 DOI: 10.1186/s13287-019-1258-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
13 Öztürk S, Elçin AE, Elçin YM. Functions of Mesenchymal Stem Cells in Cardiac Repair. Adv Exp Med Biol 2021;1312:39-50. [PMID: 33330961 DOI: 10.1007/5584_2020_598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Forsberg MH, Kink JA, Hematti P, Capitini CM. Mesenchymal Stromal Cells and Exosomes: Progress and Challenges. Front Cell Dev Biol 2020;8:665. [PMID: 32766255 DOI: 10.3389/fcell.2020.00665] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
15 Qiu L, Xie M, Zhou M, Liu X, Hu Z, Wu L. Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCs. Front Cell Dev Biol 2021;9:630353. [PMID: 33644070 DOI: 10.3389/fcell.2021.630353] [Reference Citation Analysis]
16 Jayaraj JS, Janapala RN, Qaseem A, Usman N, Fathima N, Kashif T, Reddy VK, Bakshi S. Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019. Cureus 2019;11:e5585. [PMID: 31696004 DOI: 10.7759/cureus.5585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Fanaroff AC, Morrow V, Krucoff MW, Seltzer JH, Perin EC, Taylor DA, Miller LW, Zeiher AM, Fernández-Avilés F, Losordo DW, Henry TD, Povsic TJ. A Path Forward for Regenerative Medicine. Circ Res 2018;123:495-505. [PMID: 30355250 DOI: 10.1161/CIRCRESAHA.118.313261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jin L, Zhang J, Deng Z, Liu J, Han W, Chen G, Si Y, Ye P. Mesenchymal stem cells ameliorate myocardial fibrosis in diabetic cardiomyopathy via the secretion of prostaglandin E2. Stem Cell Res Ther. 2020;11:122. [PMID: 32183879 DOI: 10.1186/s13287-020-01633-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
19 Cheung MM, Jahan N. Can Stem Cells Improve Left Ventricular Ejection Fraction in Heart Failure? A Literature Review of Skeletal Myoblasts and Bone Marrow-Derived Cells. Cureus 2020;12:e11598. [PMID: 33364119 DOI: 10.7759/cureus.11598] [Reference Citation Analysis]
20 Mostafavian Z, Vakilian F, Torkmanzade L, Moghiman T. Effect of Stem Cell Therapy on Patients' Quality of Life in Heart Failure with Reduced Ejection Fraction. J Med Life 2018;11:359-64. [PMID: 30894895 DOI: 10.25122/jml-2018-0013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Alvarez P, Tang WW. Recent Advances in Understanding and Managing Cardiomyopathy. F1000Res 2017;6:1659. [PMID: 28928965 DOI: 10.12688/f1000research.11669.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Himeno T, Kamiya H, Nakamura J. Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy? Curr Diab Rep 2018;18:3. [PMID: 29383511 DOI: 10.1007/s11892-018-0971-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Li J, Hu S, Cheng K. Engineering better stem cell therapies for treating heart diseases. Ann Transl Med 2020;8:569. [PMID: 32775370 DOI: 10.21037/atm.2020.03.44] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9:17-27. [PMID: 31804767 DOI: 10.1002/sctm.19-0202] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 29.7] [Reference Citation Analysis]
25 Zhang Y, Guo L, Han S, Chen L, Li C, Zhang Z, Hong Y, Zhang X, Zhou X, Jiang D, Liang X, Qiu J, Zhang J, Li X, Zhong S, Liao C, Yan B, Tse HF, Lian Q. Adult mesenchymal stem cell ageing interplays with depressed mitochondrial Ndufs6. Cell Death Dis 2020;11:1075. [PMID: 33323934 DOI: 10.1038/s41419-020-03289-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
26 Banerjee MN, Bolli R, Hare JM. Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions. Circ Res 2018;123:266-87. [PMID: 29976692 DOI: 10.1161/CIRCRESAHA.118.311217] [Cited by in Crossref: 71] [Cited by in F6Publishing: 43] [Article Influence: 23.7] [Reference Citation Analysis]
27 Wiese DM, Wood CA, Braid LR. From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting. Front Cell Dev Biol 2022;10:867426. [DOI: 10.3389/fcell.2022.867426] [Reference Citation Analysis]
28 Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JM, Jun HW, Yoon YS, Bursac N, Prabhu SD, Dorn GW 2nd, Bolli R, Kitsis RN, Zhang J. Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. J Am Coll Cardiol 2017;70:766-75. [PMID: 28774384 DOI: 10.1016/j.jacc.2017.06.012] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
29 Feldman AM, Mann DL. Restoring public trust in scientific research by reducing conflicts of interest. J Clin Invest 2019;129:3971-3. [PMID: 31449057 DOI: 10.1172/JCI131448] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Hotham WE, Henson FMD. The use of large animals to facilitate the process of MSC going from laboratory to patient-'bench to bedside'. Cell Biol Toxicol 2020;36:103-14. [PMID: 32206986 DOI: 10.1007/s10565-020-09521-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ghiroldi A, Piccoli M, Cirillo F, Monasky MM, Ciconte G, Pappone C, Anastasia L. Cell-Based Therapies for Cardiac Regeneration: A Comprehensive Review of Past and Ongoing Strategies. Int J Mol Sci 2018;19:E3194. [PMID: 30332812 DOI: 10.3390/ijms19103194] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
32 Franceschetti T, De Bari C. The potential role of adult stem cells in the management of the rheumatic diseases. Ther Adv Musculoskelet Dis. 2017;9:165-179. [PMID: 28717403 DOI: 10.1177/1759720x17704639] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
33 Miceli V, Bulati M, Iannolo G, Zito G, Gallo A, Conaldi PG. Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. Int J Mol Sci 2021;22:E763. [PMID: 33466583 DOI: 10.3390/ijms22020763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
34 Pandey AC, Lancaster JJ, Harris DT, Goldman S, Juneman E. Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells. Stem Cells Int 2017;2017:9640108. [PMID: 29391871 DOI: 10.1155/2017/9640108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
35 Williams R. Circulation Research "In This Issue" Anthology. Circ Res 2018;122:e92-e118. [PMID: 29880503 DOI: 10.1161/RES.0000000000000211] [Reference Citation Analysis]
36 Poomani MS, Mariappan I, Perumal R, Regurajan R, Muthan K, Subramanian V. Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier. Global Heart 2022;17:19. [DOI: 10.5334/gh.1098] [Reference Citation Analysis]
37 Tang XL, Wysoczynski M, Gumpert AM, Li Y, Wu WJ, Li H, Stowers H, Bolli R. Effect of intravenous cell therapy in rats with old myocardial infarction. Mol Cell Biochem 2021. [PMID: 34783963 DOI: 10.1007/s11010-021-04283-2] [Reference Citation Analysis]
38 Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res 2017;121:1192-204. [PMID: 28974553 DOI: 10.1161/CIRCRESAHA.117.310712] [Cited by in Crossref: 153] [Cited by in F6Publishing: 102] [Article Influence: 30.6] [Reference Citation Analysis]
39 Diaz-Navarro R, Urrútia G, Cleland JG, Poloni D, Villagran F, Acosta-Dighero R, Bangdiwala SI, Rada G, Madrid E. Stem cell therapy for dilated cardiomyopathy. Cochrane Database Syst Rev 2021;7:CD013433. [PMID: 34286511 DOI: 10.1002/14651858.CD013433.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Lemcke H, Voronina N, Steinhoff G, David R. Recent Progress in Stem Cell Modification for Cardiac Regeneration. Stem Cells Int 2018;2018:1909346. [PMID: 29535769 DOI: 10.1155/2018/1909346] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
41 Traverse JH. Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy? Circ Res 2017;120:256-8. [PMID: 28104762 DOI: 10.1161/CIRCRESAHA.116.310342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
42 Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019;50:2835-2841. [PMID: 31495331 DOI: 10.1161/strokeaha.119.026318] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
43 Perucca Orfei C, Talò G, Viganò M, Perteghella S, Lugano G, Fabro Fontana F, Ragni E, Colombini A, De Luca P, Moretti M, Torre ML, de Girolamo L. Silk/Fibroin Microcarriers for Mesenchymal Stem Cell Delivery: Optimization of Cell Seeding by the Design of Experiment. Pharmaceutics 2018;10:E200. [PMID: 30352986 DOI: 10.3390/pharmaceutics10040200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
44 Razazian M, Khosravi M, Bahiraii S, Uzan G, Shamdani S, Naserian S. Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells. World J Stem Cells 2021; 13(8): 971-984 [PMID: 34567420 DOI: 10.4252/wjsc.v13.i8.971] [Reference Citation Analysis]
45 Hamid HA, Sarmadi VH, Prasad V, Ramasamy R, Miskon A. Electromagnetic field exposure as a plausible approach to enhance the proliferation and differentiation of mesenchymal stem cells in clinically relevant scenarios. J Zhejiang Univ Sci B 2022;23:42-57. [PMID: 35029087 DOI: 10.1631/jzus.B2100443] [Reference Citation Analysis]
46 Ozay EI, Vijayaraghavan J, Gonzalez-Perez G, Shanthalingam S, Sherman HL, Garrigan DT Jr, Chandiran K, Torres JA, Osborne BA, Tew GN, Slukvin II, Macdonald RA, Kelly K, Minter LM. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res 2019;35:101401. [PMID: 30738321 DOI: 10.1016/j.scr.2019.101401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
47 Yousefi-ahmadipour A, Asadi F, Pirsadeghi A, Nazeri N, Vahidi R, Abazari MF, Afgar A, Mirzaei-parsa MJ. Current Status of Stem Cell Therapy and Nanofibrous Scaffolds in Cardiovascular Tissue Engineering. Regen Eng Transl Med . [DOI: 10.1007/s40883-021-00230-1] [Reference Citation Analysis]
48 Liu Y, Niu R, Li W, Lin J, Stamm C, Steinhoff G, Ma N. Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases. Cell Mol Life Sci. 2019;76:1681-1695. [PMID: 30721319 DOI: 10.1007/s00018-019-03019-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
49 Nowak-stępniowska A, Osuchowska PN, Fiedorowicz H, Trafny EA, Gan Y. Insight in Hypoxia-Mimetic Agents as Potential Tools for Mesenchymal Stem Cell Priming in Regenerative Medicine. Stem Cells International 2022;2022:1-24. [DOI: 10.1155/2022/8775591] [Reference Citation Analysis]
50 Campos de Carvalho AC, Kasai-Brunswick TH, Bastos Carvalho A. Cell-Based Therapies for Heart Failure. Front Pharmacol 2021;12:641116. [PMID: 33912054 DOI: 10.3389/fphar.2021.641116] [Reference Citation Analysis]
51 Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis 2020;11:349. [PMID: 32393744 DOI: 10.1038/s41419-020-2542-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
52 Epstein SE, Luger D, Lipinski MJ. Paracrine-Mediated Systemic Anti-Inflammatory Activity of Intravenously Administered Mesenchymal Stem Cells: A Transformative Strategy for Cardiac Stem Cell Therapeutics. Circ Res 2017;121:1044-6. [DOI: 10.1161/circresaha.117.311925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
53 Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. Cells. 2019;8:886. [PMID: 31412678 DOI: 10.3390/cells8080886] [Cited by in Crossref: 203] [Cited by in F6Publishing: 173] [Article Influence: 67.7] [Reference Citation Analysis]
54 Juárez-Navarro KJ, Padilla-Camberos E, Díaz NF, Miranda-Altamirano A, Díaz-Martínez NE. Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2. Stem Cells Int 2020;2020:8892189. [PMID: 33414832 DOI: 10.1155/2020/8892189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
55 Sharma A, Gupta S, Archana S, Verma RS. Emerging Trends in Mesenchymal Stem Cells Applications for Cardiac Regenerative Therapy: Current Status and Advances. Stem Cell Rev Rep 2022. [PMID: 35122226 DOI: 10.1007/s12015-021-10314-8] [Reference Citation Analysis]
56 Netsch P, Elvers-Hornung S, Uhlig S, Klüter H, Huck V, Kirschhöfer F, Brenner-Weiß G, Janetzko K, Solz H, Wuchter P, Bugert P, Bieback K. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Res Ther 2018;9:184. [PMID: 29973267 DOI: 10.1186/s13287-018-0936-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
57 Cassani M, Fernandes S, Vrbsky J, Ergir E, Cavalieri F, Forte G. Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. Front Bioeng Biotechnol 2020;8:323. [PMID: 32391340 DOI: 10.3389/fbioe.2020.00323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Wysoczynski M, Khan A, Bolli R. New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. Circ Res 2018;123:138-58. [PMID: 29976684 DOI: 10.1161/CIRCRESAHA.118.313251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 18.7] [Reference Citation Analysis]
59 Filho DM, de Carvalho Ribeiro P, Oliveira LF, Dos Santos ALRT, Parreira RC, Pinto MCX, Resende RR. Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System. Stem Cell Rev Rep 2019;15:463-73. [PMID: 31147819 DOI: 10.1007/s12015-019-09897-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
60 Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22. [PMID: 31815001 DOI: 10.1038/s41536-019-0083-6] [Cited by in Crossref: 309] [Cited by in F6Publishing: 305] [Article Influence: 103.0] [Reference Citation Analysis]